MacroGenics, Inc.
MGNXDrugs in Pipeline
7
Phase 3 Programs
3
Upcoming Catalysts
2
Next Catalyst
Feb 2027
Market Overview
Stock performance and key metrics
2 upcoming, 1 past
How MGNX's past catalysts played out
Teplizumab
Type 1 Diabetes Mellitus
Margetuximab
HER-2 Positive Breast Cancer
Retifanlimab
Gastric Cancer
Margetuximab 10 mg/kg
Gastric Cancer
MGD007 + MGA012
Colorectal Cancer Metastatic
vobramitamab duocarmazine 2.0 mg (Arm A)
Castration-Resistant Prostatic Cancer
lorigerlimab
Androgen-Independent Prostatic Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Teplizumab | Phase 3 | Type 1 Diabetes Mellitus | - | - |
Margetuximab | Phase 3 | HER-2 Positive Breast Cancer | - | - |
Retifanlimab | Phase 3 | Gastric Cancer | - | - |
Margetuximab 10 mg/kg | Phase 2 | Gastric Cancer | - | - |
MGD007 + MGA012 | Phase 2 | Colorectal Cancer Metastatic | - | - |
vobramitamab duocarmazine 2.0 mg (Arm A) | Phase 2 | Castration-Resistant Prostatic Cancer | - | - |
lorigerlimab | Phase 2 | Androgen-Independent Prostatic Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in MacroGenics, Inc.'s drug pipeline?→
CatalystAlert tracks 7 drug candidates in MacroGenics, Inc.'s (MGNX) pipeline across Phase 3, Phase 2. Its lead program is Teplizumab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is MacroGenics, Inc.'s next FDA catalyst?→
MacroGenics, Inc.'s (MGNX) next tracked catalyst is a Phase 2 expected September 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MGNX biotech catalysts?→
Add MGNX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow MacroGenics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.